Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
September 25 2023 - 4:30PM
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome
editing company, today announced the grant of an inducement award
to the Company’s newly appointed Chief Commercial and Strategy
Officer, Caren Deardorf. In connection with Ms. Deardorf’s
appointment, the Editas Medicine Board of Directors approved a
stock option grant to Ms. Deardorf as an inducement material
to Ms. Deardorf entering into employment with Editas
Medicine in accordance with Nasdaq Listing Rule
5635(c)(4). The stock option provides for the purchase of up
to 123,350 shares of Editas Medicine common stock at a
price of $8.00 per share, the closing price per share
of Editas Medicine common stock as reported by Nasdaq
on the date of grant, and vests over four years, with 25
percent of the shares vesting on the first anniversary of Ms.
Deardorf’s employment start date, and the remainder vesting ratably
at the end of each subsequent month thereafter, subject to Ms.
Deardorf’s continued service relationship with Editas
Medicine through the applicable vesting dates.
About Editas MedicineAs a clinical-stage genome
editing company, Editas Medicine is focused on translating the
power and potential of the CRISPR/Cas12a and Cas9 genome editing
systems into a robust pipeline of treatments for people living with
serious diseases around the world. Editas Medicine aims to
discover, develop, manufacture, and commercialize transformative,
durable, precision genomic medicines for a broad class of diseases.
Editas Medicine is the exclusive licensee of Broad Institute’s
Cas12a patent estate and Broad Institute and Harvard University’s
Cas9 patent estates for human medicines. For the latest information
and scientific presentations, please visit
www.editasmedicine.com.
Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Apr 2024 to May 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From May 2023 to May 2024